Twist Bioscience (TWST) net assets (shareholders' equity)

Net assets · fiscal 2026
$888.02M

Twist Bioscience (TWST) had net assets of $888.02M at the end of fiscal 2026 (September 30, 2026). That is 87.8% higher than the $472.96M of fiscal 2025. Figures as of 19 Nov 2026, 11:31 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2026
$888.02M
Change on fiscal 2025
+87.8%
Growth, 5 years
+8.9% a year
Highest on record
$888.02Mfiscal 2026
Lowest on record
-$201.42Mfiscal 2018
Fiscal years on record
102017–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Twist Bioscience net assets (shareholders' equity), in more detail

Over the five fiscal years to 2026 net assets grew at a compound 8.9% a year. Across the 10 fiscal years on record (2017–2026), the highest was $888.02M in fiscal 2026 and the lowest -$201.42M in fiscal 2018.

History · 10 fiscal years

Net assets by fiscal year

Twist Bioscience net assets (shareholders' equity), year by year

Twist Bioscience (TWST) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2026$888.02M 87.8% up
2025$472.96M 0.1% up
2024$472.69M 24.2% down
2023$623.43M 21.0% down
2022$789.39M 35.9% up
2021$580.82M 72.7% up
2020$336.26M 121.1% up
2019$152.08M—
2018-$201.42M—
2017-$133.36M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Twist Bioscience and comparable companies
CompanyNet assetsFiscal year
TG Therapeutics TGTX$648.02M2025
Praxis Precision Medicines PRAX$878.14M2025
Twist Bioscience TWST$888.02M2026
Protagonist Therapeutics PTGX$614.71M2025
Krystal Biotech KRYS$1.22B2025
10x Genomics TXG$796.33M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TWST

Twist Bioscience, figure by figure

Twist Bioscience (TWST) overview: price, valuation and scorecardAll health care companies by market value

Twist Bioscience net assets (shareholders' equity): questions and answers

What are Twist Bioscience's net assets?

Twist Bioscience (TWST) had net assets of $888.02M at the end of fiscal 2026 (September 30, 2026). That is 87.8% higher than the $472.96M of fiscal 2025.

What is the growth rate of Twist Bioscience's net assets?

Over the five fiscal years to 2026 net assets grew at a compound 8.9% a year.

What are the highest and lowest net assets figures on record for Twist Bioscience?

Across the 10 fiscal years on record (2017–2026), the highest was $888.02M in fiscal 2026 and the lowest -$201.42M in fiscal 2018.

How is Twist Bioscience's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Twist Bioscience it is on record here for 10 fiscal years, 2017 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Twist Bioscience (TWST) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/TWST/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.